Scripscan:Marksans Pharma Ltd
cmp:5
Code:524404
Story:The main focus market for the Company is US,UK,australia,New Zealand, Germany and other European markets.It is also eying to tab huge Russian and CIS markets and has started dossier filling in these countries.With the approval of prestigious US FDA and UK MHRA, the Company has actively started exporting formulation products to US and UK and has tied up with renowned players in US and UK for supply of OTC as well as prescription products.About 70% of export turnover is from UK. Besides, acquisition of Bell,Sons & Co.(Druggists) Limited and Relonchem Limited has given more muscle to the Company in UK market.The Company has already registered 5 products in the Australian markets and is also applying for registration of drugs which are shortly going off patent in Australia.Australia and New Zealand markets are the second highest revenue earner for exports after UK.Marksans is also expanding its business in the rest of the European markets through CRAMS and active products registration.The Company has a strong back up in terms of its formulation development and R&D team aligning itself to aggressive market strategies. New product development for the European and US markets are Metformin XR,Dutasteride, Isotrelinoin,Paricullitol, whose patents are nearing expiry and show good market potential in terms of value and volume.Recently acquired Bell,Sons & Co (Druggists) Limited's products are being introduced to bigger market in South East Asia and Africa.The Company started its business in the semi regulated markets in the year2008and filed more than 250 registrations across all semi regulated markets.It has already got 45 products registered and 205 are awaiting registration in countries like Cambodia,Philippines,Vietnam, SriLanka, Kenya, Tanzania, Ukraine,Russia, Hongkong and Nigeria.Further, statutory compliances are in process for entering in other countries.All this developments should translate into good growth for the company in the coming years.At 5rs, I feel one can hold on to the stock and can add more if it drifts near its 52 week low of 3rs.
Important Disclaimer&Privacy policy
This blog does not share personal information with third parties nor do we store any information about your visit to this blog other than to analyze and optimize your content and reading experience through the use of cookies.You can turn off the use of cookies at anytime by changing your specific browser settings.This privacy policy is subject to change without notice and was last updated on 20.3.2013. If you have any questions, feel free to contact me directly here: arunsharemarket@gmail.com
Investment in equity shares has its own risks.Sincere efforts have been made to present the right investment perspective.The information contained herein is based on analysis and up on sources that I consider reliable. I,however,do not vouch for the accuracy or the completeness thereof.This material is for personal information and am not responsible for any loss incurred based upon it & take no responsibility whatsoever for any financial profits or loss which may arise from the recommendations above.The stock price projections shown are not necessarily indicative of future price performance.The information herein, together with all estimates and forecasts, can change without notice.
